Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again
Retinopathy of prematurity (ROP), a vascular proliferative disease affecting preterm infants, is a leading cause of childhood blindness. Various studies have investigated the pathogenesis of ROP. Clinical experience indicates that oxygen levels are strongly correlated with ROP development, which led...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/2/331 |
| _version_ | 1797410410311188480 |
|---|---|
| author | Mitsuru Arima Yuya Fujii Koh-Hei Sonoda |
| author_facet | Mitsuru Arima Yuya Fujii Koh-Hei Sonoda |
| author_sort | Mitsuru Arima |
| collection | DOAJ |
| description | Retinopathy of prematurity (ROP), a vascular proliferative disease affecting preterm infants, is a leading cause of childhood blindness. Various studies have investigated the pathogenesis of ROP. Clinical experience indicates that oxygen levels are strongly correlated with ROP development, which led to the development of oxygen-induced retinopathy (OIR) as an animal model of ROP. OIR has been used extensively to investigate the molecular mechanisms underlying ROP and to evaluate the efficacy of new drug candidates. Large clinical trials have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents to treat ROP, and anti-VEGF therapy is presently becoming the first-line treatment worldwide. Anti-VEGF therapy has advantages over conventional treatments, including being minimally invasive with a low risk of refractive error. However, long-term safety concerns and the risk of late recurrence limit this treatment. There is an unmet medical need for novel ROP therapies, which need to be addressed by safe and minimally invasive therapies. The recent progress in biotechnology has contributed greatly to translational research. In this review, we outline how basic ROP research has evolved with clinical experience and the subsequent emergence of new drugs. We discuss previous and ongoing trials and present the candidate molecules expected to become novel targets. |
| first_indexed | 2024-03-09T04:29:32Z |
| format | Article |
| id | doaj.art-33fc0680be59423396890ba3a8315211 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T04:29:32Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-33fc0680be59423396890ba3a83152112023-12-03T13:36:40ZengMDPI AGJournal of Clinical Medicine2077-03832021-01-0110233110.3390/jcm10020331Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back AgainMitsuru Arima0Yuya Fujii1Koh-Hei Sonoda2Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, JapanDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, JapanDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 8128582, JapanRetinopathy of prematurity (ROP), a vascular proliferative disease affecting preterm infants, is a leading cause of childhood blindness. Various studies have investigated the pathogenesis of ROP. Clinical experience indicates that oxygen levels are strongly correlated with ROP development, which led to the development of oxygen-induced retinopathy (OIR) as an animal model of ROP. OIR has been used extensively to investigate the molecular mechanisms underlying ROP and to evaluate the efficacy of new drug candidates. Large clinical trials have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents to treat ROP, and anti-VEGF therapy is presently becoming the first-line treatment worldwide. Anti-VEGF therapy has advantages over conventional treatments, including being minimally invasive with a low risk of refractive error. However, long-term safety concerns and the risk of late recurrence limit this treatment. There is an unmet medical need for novel ROP therapies, which need to be addressed by safe and minimally invasive therapies. The recent progress in biotechnology has contributed greatly to translational research. In this review, we outline how basic ROP research has evolved with clinical experience and the subsequent emergence of new drugs. We discuss previous and ongoing trials and present the candidate molecules expected to become novel targets.https://www.mdpi.com/2077-0383/10/2/331retinopathy of prematurityoxygen-induced retinopathyclinical trialtranslational research |
| spellingShingle | Mitsuru Arima Yuya Fujii Koh-Hei Sonoda Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again Journal of Clinical Medicine retinopathy of prematurity oxygen-induced retinopathy clinical trial translational research |
| title | Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again |
| title_full | Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again |
| title_fullStr | Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again |
| title_full_unstemmed | Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again |
| title_short | Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again |
| title_sort | translational research in retinopathy of prematurity from bedside to bench and back again |
| topic | retinopathy of prematurity oxygen-induced retinopathy clinical trial translational research |
| url | https://www.mdpi.com/2077-0383/10/2/331 |
| work_keys_str_mv | AT mitsuruarima translationalresearchinretinopathyofprematurityfrombedsidetobenchandbackagain AT yuyafujii translationalresearchinretinopathyofprematurityfrombedsidetobenchandbackagain AT kohheisonoda translationalresearchinretinopathyofprematurityfrombedsidetobenchandbackagain |